Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

  • Former head of psychiatry products at FDA joins Cybin team.
  • Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz).

A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory pathway as it studies and develops psychedelic medicines, says Alex Belser, Cybin’s chief clinical officer.

“Psychedelic medicines don’t fit neatly into the old models for how drugs are studied, reviewed and approved,” says Belser. “We brought together experts to help us work within existing clinical and regulatory frameworks while realizing that psychedelics require innovative methods and a new approach.”

During his tenure at the FDA, Laughren supervised the research and review of all new psychiatric drug applications and development projects in clinical testing. In addition, he assisted in the design and interpretation of clinical trials for psychiatric drugs. Laughren left the FDA in 2021 to start his own consulting company and has spent the last decade helping psychiatric pharmaceutical drug makers gain FDA approval for new drugs.

Cybin CEO Doug Drysdale notes that Laughren’s FDA experience is invaluable as the company moves into the “next chapter” with studies on psilocybin, the psychedelic compound found in “magic” mushrooms. “Building and maintaining strong relationships and communications channels with regulators will be important for Cybin as their understanding of psychedelic therapeutics evolves over time,” says Drysdale. 

Although Cybin is currently conducting studies on psilocybin, the company is also developing novel molecules based on other psychedelic compounds. In fact, the company has 13 provisional patent applications filed for novel psychedelic molecules.

Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050